Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > NASDAQ

<< Previous

Bullboard Posts

Next >>

Post by WalkOverTheStrton Mar 23, 2021 9:43am

400 Views

Post# 32857195

NASDAQ

Bets on whether a USA and / or European partner will be announced before NASDAQ (fall?) or after. If it is after then I'd see the stock languishing over the summer. Too much over hand from warrants, shot sellers from offering and limits of funds that can buy these shares...

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China